Cargando…

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation

Moving from indication to transplantation is a critical process in myelofibrosis. Most of guidelines specifically focus on either myelofibrosis disease or transplant procedure, and, currently, no distinct indication for the management of MF candidates to transplant is available. Nevertheless, this p...

Descripción completa

Detalles Bibliográficos
Autores principales: Polverelli, Nicola, Farina, Mirko, D’Adda, Mariella, Damiani, Enrico, Grazioli, Luigi, Leoni, Alessandro, Malagola, Michele, Bernardi, Simona, Russo, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834299/
https://www.ncbi.nlm.nih.gov/pubmed/35159362
http://dx.doi.org/10.3390/cells11030553
_version_ 1784649152753303552
author Polverelli, Nicola
Farina, Mirko
D’Adda, Mariella
Damiani, Enrico
Grazioli, Luigi
Leoni, Alessandro
Malagola, Michele
Bernardi, Simona
Russo, Domenico
author_facet Polverelli, Nicola
Farina, Mirko
D’Adda, Mariella
Damiani, Enrico
Grazioli, Luigi
Leoni, Alessandro
Malagola, Michele
Bernardi, Simona
Russo, Domenico
author_sort Polverelli, Nicola
collection PubMed
description Moving from indication to transplantation is a critical process in myelofibrosis. Most of guidelines specifically focus on either myelofibrosis disease or transplant procedure, and, currently, no distinct indication for the management of MF candidates to transplant is available. Nevertheless, this period of time is crucial for the transplant outcome because engraftment, non-relapse mortality, and relapse incidence are greatly dependent upon the pre-transplant management. Based on these premises, in this review, we will go through the path of identification of the MF patients suitable for a transplant, by using disease-specific prognostic scores, and the evaluation of eligibility for a transplant, based on performance, comorbidity, and other combined tools. Then, we will focus on the process of donor and conditioning regimens’ choice. The pre-transplant management of splenomegaly and constitutional symptoms, cytopenias, iron overload and transplant timing will be comprehensively discussed. The principal aim of this review is, therefore, to give a practical guidance for managing MF patients who are potential candidates for allo-HCT.
format Online
Article
Text
id pubmed-8834299
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88342992022-02-12 How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation Polverelli, Nicola Farina, Mirko D’Adda, Mariella Damiani, Enrico Grazioli, Luigi Leoni, Alessandro Malagola, Michele Bernardi, Simona Russo, Domenico Cells Review Moving from indication to transplantation is a critical process in myelofibrosis. Most of guidelines specifically focus on either myelofibrosis disease or transplant procedure, and, currently, no distinct indication for the management of MF candidates to transplant is available. Nevertheless, this period of time is crucial for the transplant outcome because engraftment, non-relapse mortality, and relapse incidence are greatly dependent upon the pre-transplant management. Based on these premises, in this review, we will go through the path of identification of the MF patients suitable for a transplant, by using disease-specific prognostic scores, and the evaluation of eligibility for a transplant, based on performance, comorbidity, and other combined tools. Then, we will focus on the process of donor and conditioning regimens’ choice. The pre-transplant management of splenomegaly and constitutional symptoms, cytopenias, iron overload and transplant timing will be comprehensively discussed. The principal aim of this review is, therefore, to give a practical guidance for managing MF patients who are potential candidates for allo-HCT. MDPI 2022-02-05 /pmc/articles/PMC8834299/ /pubmed/35159362 http://dx.doi.org/10.3390/cells11030553 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Polverelli, Nicola
Farina, Mirko
D’Adda, Mariella
Damiani, Enrico
Grazioli, Luigi
Leoni, Alessandro
Malagola, Michele
Bernardi, Simona
Russo, Domenico
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
title How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
title_full How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
title_fullStr How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
title_full_unstemmed How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
title_short How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation
title_sort how we manage myelofibrosis candidates for allogeneic stem cell transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834299/
https://www.ncbi.nlm.nih.gov/pubmed/35159362
http://dx.doi.org/10.3390/cells11030553
work_keys_str_mv AT polverellinicola howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT farinamirko howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT daddamariella howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT damianienrico howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT grazioliluigi howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT leonialessandro howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT malagolamichele howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT bernardisimona howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation
AT russodomenico howwemanagemyelofibrosiscandidatesforallogeneicstemcelltransplantation